Abstract:Objective To observe the ultrastructural features of recessive dystrophic epidermolysis bullosa inversa(RDEB-Ⅰ)and to detect the mutations of COL7A1 gene in a family with RDEB-Ⅰ.Methods A 24-year-old male patient complained of recurrent vesicles in the skin for 24 years.The lesions began as generalized pruritic vesicles and bullae soon after birth,with a predilection for areas subject to friction,and showed a trend to be worse in summer but mild in winter.No photosensitivity was observed.When he was 3 to 4 years old,the lesions were decreased in number,with the only involvement of the trunk and abdomen;thereafter,the lesions were improved year by year.The patient suffered from nephritis at the age of 5 years,which progressed into renal failure at the age of 15 years.He received renal transplantation and was given long-term oral tacrolimus and mycophenolate mofetil,which leaded to an improvement in the lesions.The family history was unremarkable,and the marriage between her parents was not consanguineous.Dermatological examination revealed large areas of irregularly-marginated,hypopigmented,atrophic scar on the waist,back and abdomen with onychodystrophy involving multiple nails.No vesicles were observed.Immunofluorescence antigen mapping and transmission electron microscopy were conducted to observe the expression of type Ⅶ collagen in and ultrastructure of cutaneous lesions from the patient.Venous blood samples were obtained from the patient as well as his parents and 3 sisters,and drill biopsy specimens were obtained from the margin of vesicular lesions and unaffected anterior tibial skin of the patient.DNA specimens were obtained from the blood samples of the family members and 150 unrelated healthy controls,and RNA was extracted from the biopsy samples of the patient.PCR and direct sequencing were carried out to detect mutations in COL7A1 gene,and reverse transcription-PCR was conducted to confirm the mutation at mRNA level.Results Skin cleavage was observed under lamina densa in the dermis,with a decrease in anchoring fibrils and expression of type Ⅶ collagen in the lesions of the patient.A heterozygous synonymous mutation c.C5499T which created a new splicing site and leaded to a premature terminal codon,as well as a heterozygous missense mutation c.C6205T(C-T transition at codon 2069:CGT to TGT)which leaded to the substitution of arginine by cysteine,were identified in the COL7A1 gene of the proband and all of his sisters,but not in any of the unrelated controls.The c.C5499T and c.C6205T mutations were inherited from the patient's father and mother respectively.Conclusion The compound heterozygous mutations c.C6205T and c.C5499T may be responsible for RDEB-Ⅰ in this patient.

Generation of the Induced Pluripotent Stem Cell Line (Zsphari001-A) from a Patient with Recessive Dystrophic Epidermolysis Bullosa Carrying Compound Heterozygous Mutation in the COL7A1 Gene.

398 A Simple, Efficient Non-Viral Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

Development of Minicircle Vectors Encoding COL7A1 Gene with Human Promoters for Non-Viral Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa.

455 Non-viral Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa: Hyper Branched Aminated Polyesters Mediated Minicircle DNA Delivery

CRISPR-Cas9-based Non-Viral Gene Editing Therapy for Topical Treatment of Recessive Dystrophic Epidermolysis Bullosa

901 Non-viral Gene Editing Therapy for Recessive Dystrophic Epidermolysis Bullosa: CRISPR/Cas9 Mediated COL7A1 Exon 80 Deletion Strategy

Efficient and Robust Highly Branched Poly(β-amino Ester)/minicircle COL7A1 Polymeric Nanoparticles for Gene Delivery to Recessive Dystrophic Epidermolysis Bullosa Keratinocytes

834 CRISPR/Cas9 Based COL7A1 Genomic Editing in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Via Non-Viral Polymer Delivery System

836 Non-viral Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Using a Highly Branched Poly(β-Amino Ester) Polymer (HPAE-EB)

Generation of an Induced Pluripotent Stem Cell Line (Zjulli003-A) from a Hypertrophic Cardiomyopathy Patient Carrying MYH7/c.4384G > A Mutation

200 A Comparison of Minicircle Vectors Expressing COL7A1 under the Control of Human Promoters for the Treatment of Recessive Dystrophic Epidermolysis Bullosa

Highly Efficient Ex Vivo Correction of COL7A1 through Ribonucleoprotein-Based CRISPR/Cas9 and Homology-Directed Repair to Treat Recessive Dystrophic Epidermolysis Bullosa

Rescue of the mucocutaneous manifestations by human cord blood derived nonhematopoietic stem cells in a mouse model of recessive dystrophic epidermolysis bullosa

Site-specific genome editing for correction of induced pluripotent stem cells derived from dominant dystrophic epidermolysis bullosa

Gene therapy: pursuing restoration of dermal adhesion in recessive dystrophic epidermolysis bullosa.

Induced pluripotent stem cell (iPSC) line MLi005-A derived from a patient with dominant dystrophic epidermolysis bullosa (DDEB)

Analysis of COL7A1 Gene Mutations in a Family with Recessive Dystrophic Epidermolysis Bullosa Inversa

Therapeutic base editing and prime editing of COL7A1 mutations in recessive dystrophic epidermolysis bullosa

Histological and molecular restoration of type VII collagen in Recessive dystrophic epidermolysis bullosa mouse skin by topical injection of keratinocyte-like cells differentiated from human adipose-derived mesenchymal stromal cells

CRISPR/Cas9-based targeted genome editing for correction of recessive dystrophic epidermolysis bullosa using iPS cells

An RNA-targeted therapy for dystrophic epidermolysis bullosa